An Open Label, Randomized, Multiple-Dose, Parallel Study To Evaluate The Safety And Efficacy Of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) And Taxotere (Docetaxel Injection Concentrate, Aventis Pharma Ltd.) in Locally Advanced or Metastatic Breast Cancer Patients after failure of prior chemotherapy.

Trial Profile

An Open Label, Randomized, Multiple-Dose, Parallel Study To Evaluate The Safety And Efficacy Of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) And Taxotere (Docetaxel Injection Concentrate, Aventis Pharma Ltd.) in Locally Advanced or Metastatic Breast Cancer Patients after failure of prior chemotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Dec 2010 Status changed from not yet recruiting to recruiting Clinical Trials Registry - India.
    • 06 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top